The US Congress can make “straightforward changes to speed the development and use of cost-saving biosimilars,” former US Food and Drug Administration commissioner Scott Gottlieb has argued in an opinion piece published in the Wall Street Journal. Gottlieb was responding to an earlier article by Peter Bach and Mark Trusheim that suggested it was “time to throw in the towel on biosimilars.”
Outlining his proposals for legislative fixes, Gottlieb says Congress could first “pass a law mandating that brand companies sell their...






